A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

← catalyst calendar

NCT05371964 · readout ≤ 193 d

Sponsored by Geron Corporation (industry) · GERN — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

36estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-05-04

actual

When the study began enrolling

Primary completion

Feb 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Aug 2028

estimated

The whole study's end, after follow-up

First posted

2022-05-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-01-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Myelofibrosis

Interventions

Drug: Imetelstat sodium — also filed as GRN163L
Drug: Ruxolitinib

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Incidence, Type, and Severity of Adverse Events, Including Dose-limiting Toxicity (DLT) During the DLT Observation Period and/or Study Treatment

measured 28 days after first dose

Part 2: Number of Participants With Treatment-emergent Adverse Event (AE)

measured First dose of study treatment until 30 days after the last dose of study treatment (up to approximately 5 years)

Part 2: Symptom Response Rate at Week 24

measured Week 24

Permalink · GERN's whole pipeline · Catalyst calendar · Every registered study · What changed